UK markets closed
  • NIKKEI 225

    -4.61 (-0.01%)

    -166.52 (-0.94%)

    -1.46 (-1.86%)

    +10.90 (+0.46%)
  • DOW

    +62.29 (+0.15%)
  • Bitcoin GBP

    -1,346.39 (-2.57%)
  • CMC Crypto 200

    -29.17 (-2.11%)
  • NASDAQ Composite

    +37.98 (+0.21%)
  • UK FTSE All Share

    -15.97 (-0.36%)

Sera Prognostics Inc Reports Q1 2024 Results: A Closer Look at Financials and Strategic Moves

  • Revenue: Reported as $0 after adjustments, significantly below the estimate of $0.07 million.

  • Net Loss: Narrowed to $8.1 million from $10.6 million year-over-year, but still above the estimated net loss of $9.7 million.

  • Operating Expenses: Decreased to $9.1 million, down 20% from $11.4 million in the same quarter last year.

  • Earnings Per Share (EPS): Reported at -$0.25, which is above the estimated EPS of -$0.27.

  • Research and Development Expenses: Reduced by 10% year-over-year to $3.7 million, reflecting lower clinical study costs.

  • Selling, General and Administrative Expenses: Decreased by 26% to $5.4 million due to streamlined commercial operations.

  • Cash Position: Ended the quarter with $4.2 million in cash and cash equivalents, up from $3.9 million at the end of the previous quarter.

Sera Prognostics Inc (NASDAQ:SERA), a prominent player in the health diagnostics sector, disclosed its financial outcomes for the first quarter of 2024 on May 8, 2024. The details, available in their 8-K filing, reveal a mix of strategic advancements and financial metrics that underline the company's ongoing efforts to enhance maternal and neonatal health through innovative diagnostic solutions.

Sera Prognostics Inc Reports Q1 2024 Results: A Closer Look at Financials and Strategic Moves
Sera Prognostics Inc Reports Q1 2024 Results: A Closer Look at Financials and Strategic Moves

Company Overview

Sera Prognostics Inc, known as The Pregnancy Company, is at the forefront of developing diagnostic tests that predict the risk of premature birth, preeclampsia, and other pregnancy-related conditions. Their cutting-edge bioinformatics platform supports the development of blood-based biomarker tests, which are crucial for early and personalized healthcare interventions.

Financial Performance

The first quarter of 2024 saw Sera Prognostics grappling with revenue challenges, primarily due to adjustments related to older accounts, resulting in net revenue rounding down to nil. This is a stark contrast to the $100,000 reported in the same quarter the previous year. Despite this, the company managed to reduce its total operating expenses by 20% to $9.1 million, down from $11.4 million in Q1 2023, reflecting effective cost management strategies in both research and development and administrative domains.


Net loss for the quarter was $8.1 million, a 24% improvement from the $10.6 million loss recorded in the first quarter of 2023. This reduction in net loss is a positive signal, indicating efficiency improvements and tighter control over operational costs.

Strategic Developments

Amidst these financial figures, Sera Prognostics has been actively pursuing strategic initiatives aimed at broadening the adoption and application of its PreTRM Test. Noteworthy developments include the submission of PRIME study results for peer-reviewed publication and the launch of ambient whole blood collection kits. These kits are expected to reduce costs and enhance lab processing efficiency, potentially increasing the company's market reach and operational scalability.

Furthermore, Sera Prognostics is expanding its footprint by engaging with international markets and collaborating with state healthcare programs to improve pregnancy outcomes. These efforts are aligned with the company's mission to enhance healthcare delivery through predictive diagnostics.

Financial Health and Future Outlook

Examining the balance sheet, Sera Prognostics ended the quarter with $4.2 million in cash and equivalents, and a robust portfolio of marketable securities valued at approximately $81.1 million. This financial positioning supports the company's strategic initiatives and provides a cushion for further investment in research and market expansion.

The company's proactive management of operating expenses and strategic pivots to enhance product reach and efficiency could set the stage for improved financial performance in upcoming quarters. However, the zero net revenue this quarter underscores the challenges in commercializing advanced diagnostic tests and the critical need for strategic partnerships and market acceptance.


While Sera Prognostics faces significant hurdles in scaling its operations and achieving profitability, its strategic initiatives and ongoing management reforms reflect a committed approach to overcoming these challenges. The company's focus on innovation and market expansion is poised to play a crucial role in its journey towards becoming a leader in maternal and neonatal healthcare diagnostics.

For detailed insights and continuous updates on Sera Prognostics Inc, stay tuned to

Explore the complete 8-K earnings release (here) from Sera Prognostics Inc for further details.

This article first appeared on GuruFocus.